Suspension - ChuanYin High-Tech: China Seed Group intends to acquire 298 million shares, stock to resume trading [1] - HuiBoPu: Water Industry Group plans to transfer 25%-30% of company shares, stock suspended [1] - TianSheng New Materials: Major shareholder Wu Haizhou is planning significant matters that may lead to a change in control, stock suspended [2] Private Placement and Mergers - RiJiu Optoelectronics: Plans to raise no more than 800 million yuan for a project to produce 6 million square meters of functional films and to supplement working capital [3] - QuanXin Co., Ltd.: Plans to issue convertible bonds to raise no more than 1.2 billion yuan for the production of integrated products for commercial aviation transmission and communication [3] - BeiFang ChangLong: Plans to acquire 51% of Shunyi Technology, expected to constitute a major asset restructuring [3] Share Buybacks - XingChen Technology: Plans to repurchase shares for 60 million to 120 million yuan, with a maximum repurchase price of 88.90 yuan per share [4] - XinKaiYuan: Plans to repurchase shares for 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [4] External Investments and Daily Operations - RunJian Co., Ltd.: Signed a strategic cooperation framework agreement with JD Technology to expand cooperation in AI applications and intelligent computing cloud [4] - YueDianLi A: The expansion project of Huizhou Power Plant Units 5 and 6 (2×1000MW) has a total investment of 8.05 billion yuan, with Unit 5 now in operation [5] - ZhongWu Drone: Signed a contract for drone systems worth over 100 million yuan, expected to positively impact annual operating performance [6] - TianNeng Co., Ltd.: Plans to use no more than 12 billion yuan of self-owned funds for entrusted wealth management [7] - ChangHong Technology: Its subsidiary has secured over half of the procurement share from a major domestic wafer factory for semiconductor consumables by 2026 [7] - AiMeiKe: Exclusive distributor of injectable type A botulinum toxin products has obtained drug registration certificate [7] - KangTai Biology: Clinical trial application for acellular pertussis-diphtheria-tetanus combined vaccine has been accepted [8] - PaiRui Co., Ltd.: Signed a framework agreement for bulk procurement of IGBT chips, with total supply amounting to approximately 1.3 to 1.4 billion yuan for 2028, 2029, and 2030 [8] Performance Changes - JinLi YongCi: Expected net profit of 660 million to 760 million yuan in 2025, a year-on-year increase of 127%-161% due to small batch deliveries of robotic motor rotors and magnetic materials [9] - YingQu Technology: Expected net profit of 540 million to 660 million yuan in 2025, a year-on-year increase of 114.69%-162.40%, with significant fair value changes from equity investments expected to add 381 million yuan to net profit [9] - AiBiSen: Expected net profit of 240 million to 290 million yuan in 2025, a year-on-year increase of 105.32%-148.09% [9] - WenShi Co., Ltd.: Expected net profit in 2025 to decrease by 40.73%-46.12% year-on-year due to declining profits in pig and chicken farming [9]

人民财讯1月8日电，爱美客（300896）1月8日公告，1月8日，公司在中国（包括澳门和香港）独家经销 韩国 Huons BP生产的注射用A型肉毒毒素产品获得国家药监局核准签发的《药品注册证书》。 ...

人民财讯1月8日电，爱美客(300896)1月8日公告，1月8日，公司在中国（包括澳门和香港）独家经销韩 国 Huons BP生产的注射用A型肉毒毒素产品获得国家药监局核准签发的《药品注册证书》。 转自：证券时报 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 爱美客(300896.SZ)公告称，公司在中国（包括澳门和香港）独家经销的韩国Huons BioPharma Co., Ltd. 生产的注射用A型肉毒毒素产品于2026年1月8日获得国家药品监督管理局核准签发的《药品注册证 书》。该产品通过与现有产品的组合，能为客户提供更全面的综合解决方案，有利于增强公司的核心竞 争力。但该产品进口与销售受境内外法规政策、市场环境、汇率波动等因素的影响，存在不确定性。同 时，经销协议履行中可能存在因不可抗力或其他原因而延期、变更、中止或终止的风险。 ...

| 药品名称 | 药品通用名称：注射用 A 型肉毒毒素 | | | --- | --- | --- | | | 英文名/拉丁名：Botulinum Toxin Type A for Injection | | | 生产企业 | BioPharma Co., Ltd. | Huons | | 申请事项 | 药品注册(境外生产) | | | 剂型 | | 注射剂 | | 规格 | U/瓶 | 100 | | 注册分类 | 治疗用生物制品 | | | 处方药/非处方药 | | 处方药 | | 药品批准文号 | SJ20260001 | 国药准字 | | 药品批准文号有效期 | 年 月 日 2031 01 04 | 至 | | 证书编号 | 2026S00059 | | | 上市许可持有人 | BioPharma Co., Ltd. | Huons | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经 | | | | 审查，本品符合药品注册的有关要求，批准注册，发 | | | | 给药品注册证书。 | | 一、药品注册证书的基本情况 二、药品的其他相关情况 证券代码：300896 证券简称：爱美客 公 ...

Group 1 - The company, Aimeike (300896.SZ), currently has no business layout related to brain-computer interfaces [1]

Group 1 - The medical beauty sector increased by 0.6% on January 8, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - The trading volume and turnover for key stocks in the medical beauty sector were reported, with Huaxi Biological closing at 45.11, up 1.12% [1] Group 2 - The net inflow of main funds in the medical beauty sector was 21.5 million yuan, while retail funds experienced a net outflow of 16.96 million yuan [1] - Detailed fund flow data showed that Aimeike had a main fund net inflow of 15.25 million yuan, while Huaxi Biological had a net inflow of 13.26 million yuan [2] - ST Meigu experienced a significant net outflow of main funds at 7.01 million yuan, indicating a negative trend in investor sentiment [2]

Core Viewpoint - The stock of Aimeike has shown a mixed performance with a recent increase in price, but the company has reported a significant decline in revenue and net profit for the year 2025. Group 1: Stock Performance - On January 8, Aimeike's stock rose by 2.00%, reaching 148.25 yuan per share, with a trading volume of 315 million yuan and a turnover rate of 1.03%, resulting in a total market capitalization of 44.859 billion yuan [1] - Year-to-date, Aimeike's stock price has increased by 4.61%, with a 4.96% rise over the last five trading days, a 5.01% increase over the last 20 days, but a decline of 15.52% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Aimeike reported an operating revenue of 1.865 billion yuan, a year-on-year decrease of 21.49%, and a net profit attributable to shareholders of 1.093 billion yuan, down 31.05% year-on-year [2] - Since its A-share listing, Aimeike has distributed a total of 3.887 billion yuan in dividends, with 3.012 billion yuan distributed over the past three years [3] Group 3: Shareholder Information - As of December 31, Aimeike had 60,100 shareholders, a decrease of 2.71% from the previous period, with an average of 3,472 circulating shares per person, an increase of 2.78% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 6.8295 million shares (a decrease of 151,300 shares), and Huabao CSI Medical ETF, holding 4.2589 million shares (a decrease of 802,100 shares) [3]

Group 1 - The Shanghai Composite Index rose by 0.05% on January 7, with 17 industries experiencing gains, led by the comprehensive and coal sectors, which increased by 3.86% and 2.47% respectively [1] - The oil and petrochemical and non-bank financial sectors saw the largest declines, with decreases of 1.73% and 1.13% respectively [1] - The beauty and personal care industry ranked third in terms of decline for the day, falling by 1.03% [2] Group 2 - The beauty and personal care industry experienced a net outflow of 73.58 million yuan, with 29 stocks in the sector, of which only 4 rose while 24 fell [2] - The top three stocks with the largest net outflows in the beauty and personal care sector were Qingdao Kingking, Aimeike, and Furida, with outflows of 43.47 million yuan, 21.05 million yuan, and 15.05 million yuan respectively [2][3] - The stock with the highest net inflow was Shuiyang Co., with an inflow of 18.80 million yuan, followed by Perleya and Zhongshun Jierou with inflows of 10.12 million yuan and 9.53 million yuan respectively [2][3]

证券之星消息，1月7日医疗美容板块较上一交易日下跌0.74%，*ST美谷领跌。当日上证指数报收于 4085.77，上涨0.05%。深证成指报收于14030.56，上涨0.06%。医疗美容板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流出2679.3万元，游资资金净流入1374.35万元，散户 资金净流入1304.95万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | | 主力净占比 游资净流入 (元) 游资净占比 散户净流入 (元) 散户净占比 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 920982 锦波生物 | | | 2755.02万 | 12.55% | -1248.51万 | -5.69% | -439.98万 | -2.00% | | 688363 华熙生物 | | | 204.38万 | 1.30% | 771.92万 | 4. ...